| Not Yet Recruiting | Phase I/II Trial of ONC-PluReceptor NK Cells With Epcoritamab and Tafasitamab for Patients With Recurrent or R NCT07283679 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Not Yet Recruiting | Pomalidomide After CAR T-cell Therapy for the Treatment of Relapsed or Refractory CD19+ B-cell Leukemia or Lym NCT07532525 | University of Michigan Rogel Cancer Center | Phase 1 |
| Active Not Recruiting | Epcoritamab and Lenalidomide in Treating Patients With Refractory or Relapsed Immunodeficiency-Related Large B NCT06723457 | Northwestern University | Phase 2 |
| Withdrawn | Interferon-Beta-1a (FP-1201) to Prevent Toxicities After CD19-Directed CAR T-Cell Therapy NCT05936229 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |
| Recruiting | T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL) NCT06343311 | Estrella Biopharma, Inc. | Phase 1 / Phase 2 |
| Recruiting | A Study of LUCAR-20SP in Subjects With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma NCT06313957 | Peking University Cancer Hospital & Institute | Phase 1 |
| Recruiting | Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) for the Treatmen NCT05801913 | City of Hope Medical Center | Phase 1 |
| Recruiting | Loncastuximab Tesirine for the Treatment of Relapsed or Refractory B-Cell Malignancies NCT05453396 | University of Washington | Phase 2 |
| Active Not Recruiting | Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have R NCT05627245 | National Cancer Institute (NCI) | Phase 1 |
| Active Not Recruiting | Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas NCT05583149 | Patrick C. Johnson, MD | Phase 2 |
| Recruiting | Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma NCT05272384 | National Cancer Institute (NCI) | Phase 1 |
| Recruiting | CD19-Directed CAR-T Cell Therapy for the Treatment of Relapsed/Refractory B Cell Malignancies NCT04892277 | Mayo Clinic | Phase 1 |
| Withdrawn | Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lym NCT04635683 | Yazeed Sawalha | Phase 1 |
| Recruiting | A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other An NCT04970901 | ADC Therapeutics S.A. | Phase 1 |
| Enrolling By Invitation | Long-Term Follow-up Study NCT05332054 | Caribou Biosciences, Inc. | — |
| Withdrawn | CpG-STAT3 siRNA CAS3/SS3 and Localized Radiation Therapy for the Treatment of Relapsed/Refractory B-Cell NHL NCT04995536 | City of Hope Medical Center | Phase 1 |
| Recruiting | CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANT NCT04637763 | Caribou Biosciences, Inc. | Phase 1 |
| Terminated | Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refrac NCT04659044 | Academic and Community Cancer Research United | Phase 2 |
| Unknown | Modified CD19 CAR-T in Patients With Relapsed or Refractory CD19+ B-cell Malignancies NCT04684472 | Liqun Zou | Phase 1 |
| Completed | CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymph NCT04578600 | Joseph Tuscano | Phase 1 |
| Active Not Recruiting | An Early Phase Study of Venetoclax, Lenalidomide, and Rituximab/Hyaluronidase in Slow-Growing Lymphomas That H NCT04447716 | Thomas Jefferson University | Phase 1 |
| Withdrawn | Testing a New Anti-cancer Drug Combination, Entinostat and GSK525762C, for Advanced and Refractory Solid Tumor NCT03925428 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Modified Immune Cells (AFM13-NK) and A Monoclonal Antibody (AFM13) in Treating Patients With Recurrent or Refr NCT04074746 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Active Not Recruiting | CD19.CAR Allogeneic NKT for Patients With Relapsed or Refractory B-Cell Malignancies (ANCHOR) NCT03774654 | Baylor College of Medicine | Phase 1 |
| Withdrawn | CAR.CD19-CD28-zeta-2A-iCasp9-IL15-Transduced Cord Blood NK Cells, High-Dose Chemotherapy, and Stem Cell Transp NCT03579927 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Completed | Clinical Trial to Evaluate CD19 CAR T (CT032) in Patients With Relapsed and/or Refractory Non-Hodgkin's B Cell NCT03994913 | CARsgen Therapeutics Co., Ltd. | Phase 1 / Phase 2 |
| Terminated | Study of Intratumoral Selicrelumab With Atezolizumab in Patients With Refractory or Relapsed B Cell Lymphoma NCT03892525 | The Lymphoma Academic Research Organisation | Phase 1 |
| Completed | Nab-paclitaxel/Rituximab-coated Nanoparticle AR160 in Treating Patients With Relapsed or Refractory B-Cell Non NCT03003546 | Mayo Clinic | Phase 1 |
| Active Not Recruiting | Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lympho NCT03038672 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Exp NCT03277729 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |
| Terminated | huJCAR014 CAR-T Cells in Treating Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Ac NCT03103971 | Fred Hutchinson Cancer Center | Phase 1 |
| Active Not Recruiting | Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma NCT03147885 | Barbara Ann Karmanos Cancer Institute | Phase 1 / Phase 2 |
| Completed | Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma NCT02950220 | Kami Maddocks | Phase 1 |
| Active Not Recruiting | R-ICE and Lenalidomide in Treating Patients With First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphom NCT02628405 | Academic and Community Cancer Research United | Phase 1 / Phase 2 |
| Completed | Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic L NCT02332980 | Mayo Clinic | Phase 2 |
| Completed | Retrospective Analysis on Relapsed/Refractory Aggressive Non Hodgkin Lymphoma Treated With Z-BEAM Plus ASCT NCT02992223 | A.O.U. Città della Salute e della Scienza | — |
| Terminated | Safety Study to Assess AFM11 in Patients With Relapsed and/or Refractory CD19 Positive B-cell NHL NCT02106091 | Affimed GmbH | Phase 1 |
| Completed | Radiolabeled Monoclonal Antibody and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients NCT01921387 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |
| Completed | Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas NCT01897012 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Ipilimumab and Rituximab in Treating Patients With Relapsed or Refractory B-cell Lymphoma NCT01729806 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Gemcitabine Hydrochloride, Clofarabine, and Busulfan Before Donor Stem Cell Transplant in Treating Patients Wi NCT01701986 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Active Not Recruiting | Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or NCT01695941 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | High-Dose Y-90-Ibritumomab Tiuxetan Added to Reduced-Intensity Allogeneic Stem Cell Transplant Regimen for Rel NCT01434472 | Fred Hutchinson Cancer Center | Phase 2 |
| Terminated | Iodine I 131 Monoclonal Antibody BC8 Before Autologous Stem Cell Transplant in Treating Patients With Relapsed NCT00860171 | Fred Hutchinson Cancer Center | Phase 1 |
| Completed | Vorinostat, Cladribine, and Rituximab in Treating Patients With Mantle Cell Lymphoma, Relapsed Chronic Lymphoc NCT00764517 | OHSU Knight Cancer Institute | Phase 2 |